Τόμος 24 (2010) – Τεύχος 1 – Άρθρο 6 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 24 (2010) – Issue 1 – Article 6 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

1. Nuclear Medicine Department and 2. Oncology Clinic, Democritus University of Thrace, Alexandroupolis, Hellas

pharmakonpress[at]pharmakonpress[.]gr

2. Patel Y.C., Liu J.-L., Galanopoulou A.S., Papachristou D.N.: Production, action, and degradation of somatostatin. In: The Handbook of Physiology: The Endocrine Pancreas and Regulation of Metabolism (Jefferson L.S., Cherrington A.D., eds). Oxford University Press. New York (In press)

3. Weiss R.F., Reddi A.H., Nimmi M.F.: Somatostatin can locally inhibit proliferation and differentiation of cartilage and bone precursor cells. Calcif. Tissue Intern. 33: 425-430 (1981)

4. Karalis K., Mastorakos G., Chrousos G.P., Tolis G.: Somatostatin analogues suppress the inflammatory reaction in vivo. J. Clin. Invest. 93: 2000-2006 (1994)

5. Anguilla M.C., Rodriguez A.M., Anguilla-Mansilla H.N., Lee W.T.: Somatostatin antisense oligodeoxy-nucleotide mediated stimulation of lymphocyte proliferation in culture. Endocrinology 137: 1585-1590 (1996)

6. Patel Y.C., Srikant C.B.: Somatostatin receptors. Trends Endocrinol. Metab. 8: 398-405 (1997)

7. Reisine T., Bell G.I.: Molecular biology of somatostatin receptors. Endocr. Rev. 16: 427-442 (1995)

8. Stafford N.D., Condon L.T., Rogers M.J., et al.: The immunohistochemical localization of somatostatin receptors 1, 2, 3, and 5 in acoustic neuromas. J. Clin. Pathol. 57: 168-171 (2004)

9. Srikant C.B.: Human somatostatin receptor mediated antiproliferative action evokes subtype selective cytotoxic and cytostatic signaling. Yale J. Biol. Med. 70: 541-548 (1997)

10. Sharma K., Srikant C.B.: Induction of wild-type p53, Bax, and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells. Int. J. Cancer 76: 259-266 (1998)

11. Sreedharan S.P., Kodama K.T., Peterson K.E., Goetzl E.J.: Distinct sudsets of somatostatin receptors on cultured human lymphocytes. J. Biol. Chem. 264: 949-953 (1989)

12. Reubi J.C., Horisberger U., Waser B., Gebbers J.O., Laissue J.A.: Preferential location of somatostatin receptors in germinal centers of human gut lymphoid tissue. Gastroenterology 103: 1207-1214 (1992)

13. Reubi J.C., Schaer J.C., Markwalder R., Waser B.,

Horisberger U., Laissue J.A.: Distribution of somatostatin receptors in normal and neoplastic human tissues: recent advances and potential relevance. Yale J. Biol. Med. 70: 471-479 (1997)

14. Csaba Z., Dournaud P.: Cellular biology of somatostatin receptors. Neuropeptides 35: 1-23 (2001)

15. Reubi J.C: Regulatory peptide receptors as molecular targets for cancer diagnosis and therapy. Q. J. Nucl. Med. 41: 63-70 (1997)

16. Reubi J.C., Waser B., Schaer J.C., Laissue J.A.: Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur. J. Nucl. Med. 28: 836-846 2001)

17. Denzler B., Reubi J.C.: Expression of somatostatin receptors in peritumoral veins of human tumors. Cancer 85: 188-198 (1999)

18. Vanhagen P.M., Krenning E.P., Reubi J.C., Kwekkeboom D.J., Bakker W.H., Mulder A.H., Laissue I., Hoogstede H.C., Lamberts S.W.: Somatostatin analogue scintigraphy in granulomatous diseases. Eur. J. Nucl. Med. 21: 497-502 (1994)

19. Patel Y.C., Srikant C.B.: Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hSSTR1–5). Endocrinology 135: 2814-2817 (1994)

20. Hukovic N., Panetta R., Kumar U., Patel Y.C.: Agonistdependent regulation of cloned human somatostatin receptor types 1–5 (hSSTR1–5): subtype selective internalization or upregulation. Endocrinology 137: 4046-4049 (1996)

21. Nouel D., Gaudriault G., Houle M., Reisine T., Vincent J.P., Mazella J., Beaudet A.: Differential internalization of somatostatin in COS-7 cells transfected with SST1 and SST2 receptor subtypes: a confocal microscopic study using novel fluorescent somatostatin derivatives. Endocrinology 138: 296-306 (1997)

22. Hipkin R.W, Friedman J., Clark R.B., Eppler C.M., Schonbrunn A.: Agonistinduced desensitization, internalization, and phosphorylation of the SST2 A somatostatin receptor. J. Biol. Chem. 27: 13869-13876 (1997)

23. Roth A., Kreienkamp H.J., Meyerhoff W., Richter D.: Phosphorylation of four amino acid residues in the carboxyl terminus of the rat somatostatin receptor subtype 3 is crucial for its desensitization and internalization. J. Biol. Chem. 38: 23769-23774 (1997)

24. Reubi J.C., Krenning E., Lamberts S.W., Kvols L.: Somatostatin receptors in malignant tissues. J. Steroid Biochem. Mol. Biol. 37: 1073-1077 (1990)

25. Reubi J.C., Kvols L., Krenning E., Lamberts S.W.: In vitro and in vivo detection of somatostatin receptors in human malignant tissues. Acta Oncol. 30: 463-468 (1991)

26. Papotti M., Bongiovanni M., Volante M., Allìa E., Landolfi S., Helboe L., Schindler M., Cole S.L., Bussolati G.: Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors: a correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch. 440: 461-475 (2002)

27. Oda Y., Tanaka Y., Naruse T., Sasanabe R., Tsubamoto M., Funahashi H.: Expression of somatostatin receptor and effects of somatostatin analog on pancreatic endocrine tumors. Surg. Today 32: 690-694 (2002)

28. Kvols L.K., Reubi J.C., Horisberger U., Moertel C.G., Rubin J., Charboneau J.W.: The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide. Yale J. Biol. Med. 65: 505-518 (1992); discussion 531-536

29. Abrahamsson P.A.: Neuroendocrine differentiation in prostatic carcinoma. Prostate 39: 135-48 (1999)

30. Schulz S., Pauli S.U., Handel M., Dietzmann K., Firsching R., Höllt V.: Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A. Clin. Cancer Res. 6: 1865-1874 (2000)

31. Krenning E.P., Kwekkeboom D.J., Bakker W.H., Breeman W.A., Kooij P.P., Oei H.Y., van Hagen M., Postema P.T., de Jong M., Reubi J.C., et al.: Somatostatin receptor scintigraphy with [¹¹¹In-DTPA-D-Phe]- and [¹²³I-Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients. Eur. J. Nucl. Med. 20: 716-731 (1993)

32. Hukovic N., Panetta R., Kumar U., Patel Y.C.: Agonistdependent regulation of cloned human somatostatin receptor types 1-5 (hSSTR l-5): Subtype selective internalization or upregulation. Endocrinology 137: 4046-4049 (1996)

33. Nouel D., Gaudriault G., Houle M., Reisine T., Vincent J.P., Mazella J., Beaudet A.: Differential internalization of somatostatin in COS-7 cells transfected with SST1 and SST2 receptor subtypes: A confocal microscopic study using novel fluorescent somatostatin derivatives. Endocrinology 138: 296-306 (1997)

34. Krisch B., Feindt J., Mentlein R.: Immunoelectronmicroscopic analysis of the ligand-induced internalization of the somatostatin receptor subtype 2 in cultured human glioma cells. J. Histochem. Cytochem. 46: 1233-1242 (1998)

35. Hipkin R.W., Friedman J., Clark R.B., Eppler C.M., Schonbrunn A.: Agonist-induced desensitization, internalization, and phosphorylation of the sst2A somatostatin receptor. J. Biol. Chem. 272: 13869-13876 (1997)

36. Reubi J.C, Horisberger U., Studer U.E., Waser B., Laissue J.A.: Human kidney as a target for somatostatin: high affinity receptors in tubules and vasa recta. J. Endocrinol. Metab. 77: 1323-1328 (1993)

37. Menda Y., Kahn D.: Somatostatin receptor imaging of non-small cell lung cancer with 99mTc-depreotide. Semin. Nucl. Med. 32: 92-96 (2002)

38. Virgolini I., Britton K., Buscombe J., Moncayo R., Paganelli G., Riva P.: 111In- and 90Y-DOTA-Lanreotide: results and implications of the MAURITIUS trial. Semin. Nucl. Med. 32: 148-155 (2002)

39. Reubi J.C., Schaer J.C., Waser B., et al.: Affinity profiles for human somatostatin receptor sst1-sst5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur. J. Nucl. Med. 27: 273-282 (2000)

40. Virgolini I., Leimer M., Handmaker H., Lastoria S., Bischof C., Muto P., Pangerl T., Gludovacz D., Peck-Radosavljevic M., Lister-James J., Hamilton G., Kaserer K., Valent P., Dean R.: Somatostatin receptor subtype specificity and in vivo binding of a novel tumor tracer, Tc99m-P829. Cancer Res. 58: 1850-1859 (1998)

41. Kwekkeboom D.J., Bakker W.H., Kam B.L., Teunissen J.J.M., Kooij P.P., Herder W.W., Feelders R.A., Eijck C.H.J., Jong M ,Srinivasan A., Erion J.L., Krenning E.P.: Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [¹⁷⁷Lu-DOTA0,Tyr3] octreotate. Eur. J. Nucl. Med. 30: 417-422 (2003)

42. Dimitroulopoulos D., Xinopoulos D., Tsamakidis K., Zisimopoulos A., Andriotis E., Markidou S., Panagiotakos D., Chrysohoou C., Bazinis A., Paraskevas E.: The role of sandostatin LAR in treating patients with advanced hepatocellular cancer. Hepatogastroenterology 49: 1245-1250 (2002)

43. Dimitroulopoulos D., Xinopoulos D., Tsamakidis K., Zisimopoulos A., Andriotis E., Panagiotakos D., Fotopoulou A., Chrysohoou C., Bazinis A,. Daskalopoulou D., Paraskevas E.: Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo controlled trial. World J. Gastroenterol. 13: 3164-3170 (2007)

44. Dimitroulopoulos D., Xynopoulos D., Tsamakidis K., Zisimopoulos A., Andriotis E., Fotopoulou E., Kontis M., Paraskevas I.: Scintigraphic detection of carcinoid tumors with a cost effectiveness analysis. World J. Gastroenterol. 10: 3628-3633 (2004)

45. Paganelli G., Zoboli S., Cremonesi M., Bodei L., Ferrari M., Grana C., Bartolomei M., Orsi F., De Cicco C., Macke H.R., Chinol M., de Braud F.: (2001) Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide. Eur. J. Nucl. Med. 28: 426-434 (2001)

46. Valkema R., Jamar F., Jonard P., Bakker W.H., Norenberg J., Hadley J., Smith C., Kvols L., Pauwels S., Krenning E.P.: Targeted radiotherapy with 90Y-SMT487 (Octreo Ther): a phase 1 study [Abstract]. J. Nucl. Med. 41(Suppl): 111P (2000)

47. Waldherr C., Pless M., Maecke H.R., Haldemann A., Mueller-Brand J.: (2001) The clinical value of [⁹⁰Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann. Oncol. 12: 941-945 (2001)

48. Reubi J.C., Schar J.C., Waser B., Wenger S., Heppeler A., Schmitt J.S., Mäcke H.R.: Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur. J. Nucl. Med. 27: 273-282 (2000)

49. Hofland L.J., Breeman W.A., Krenning E.P., de Jong M., Waaijers M., van Koetsveld P.M., Mäcke H.R., Lamberts S.W.: Internalization of [DOTA degrees, ¹²⁵I-Tyr3] Octreotide by somatostatin receptorpositive cells in vitro and in vivo: Implications for somatostatin receptor-targeted radio-guided surgery. Proc. Assoc. Am. Physicians 111: 63-69 (1999)

50. de Jong M., Breeman W.A., Bernard B.F., van Gameren A., de Bruin E., Bakker W.H., van der Pluijm M.E., Visser T.J., Mäcke H.R., Krenning E.P.: Tumour uptake of the radiolabelled somatostatin analogue [DOTAO, TYR3] octreotide is dependent on the peptide amount. Eur. J. Nucl. Med. 26: 693-698 (1999)

51. Kwekkeboom D.J., Kooij P.P., Bakker W.H., Eppler C.M., Schonbrunn A.: Comparison of ¹¹¹In-DOTA-Tyr3-octreotide and ¹¹¹In-DTPA-octreotide in the same patients: Biodistribution, kinetics, organ and tumor uptake. J. Nucl. Med. 40: 762-767 (1999)

pharmakonpress[at]pharmakonpress[.]gr

pharmakonpress[at]pharmakonpress[.]gr